Behçet disease: Clinical features and management in a Brazilian tertiary hospital

Journal of Clinical Rheumatology

Volumn 17, Issue 8, 2011, Pages 416-420

  Oliveira, Ana Cecília Diniz ^a   Buosi, Ana Letícia Pirozzi ^a   Dutra, Lívia Almeida ^b   De Souza, Alexandre Wagner Silva ^a  

^a Rheumatology Division   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Beh et syndrome; colchicine; immunosuppressive agents; uveitis

Indexed keywords

AZATHIOPRINE; BENZATHINE PENICILLIN; CHLORAMBUCIL; CHLORHEXIDINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; INFLIXIMAB; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISONE; SUCRALFATE; THALIDOMIDE;

ADULT; ANEURYSM; ARTHRITIS; ARTICLE; BEHCET DISEASE; BRAZIL; CLINICAL FEATURE; DISEASE SEVERITY; DRUG MEGADOSE; ERYTHEMA NODOSUM; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENDER; GENITAL ULCER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MENINX DISORDER; MOUTH ULCER; NEUROLOGIC DISEASE; OBSERVATIONAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PUSTULE; RETROSPECTIVE STUDY; SKIN DEFECT; SKIN MANIFESTATION; TERTIARY HEALTH CARE; THROMBOSIS; VEIN THROMBOSIS;

ADULT; BEHCET SYNDROME; BRAZIL; COHORT STUDIES; COLCHICINE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 82455212742     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e31823a46ed     Document Type: Article

References (43)

1. Sakane T, Takeno M, Suzuki N, et al. Behçet's disease. N Engl J Med. 1999;341:1284-1291.
2. Marshall SE. Behçet's disease. Best Pract Res Clin Rheumatol. 2004;18:291-311.
3. Verity DH, Marr JE, Ohno S, et al. Behçet's disease, the Silk Road and HLA-B51: Historical and geographical perspectives. Tissue Antigens. 1999;54:213-220.
4. Mendonza-Pinto C, García-Carrasco M, Jiménez-Hernandez M, et al. Etiopathogenesis of Behçet's disease. Autoimmun Rev. 2010;9: 241-245.
5. Mendes D, Correia M, Barbedo M, et al. Behçet's diseaseVa contemporary review. Autoimmun Rev. 2009;32:178-188.
6. Hatemi G, Silman A, Bang D, et al. Management of Behçet disease: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis. 2009;68:1528-1534.
7. Hatemi G, Silman A, Bang D, et al. EULAR Recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67:1656-1662.
8. Neves FS, Caldas CAM, Lage LV, et al. Faraway from the Silk Route: Demographic and clinical features of Behçet's disease in 106 Brazilian patients. Clin Rheumatol. 2009;28:543-546.
9. Tunes RS, Amorim R, Santiago MB. Clinical aspects of Behçet's syndrome in Brazil: A review of 16 cases. Acta Rheumatol Port. 2009;34:235-240.
10. Barra C, Belfort Júnior R, Abreu MT, et al. Behçet's disease in BrazilVa review of 49 cases with emphasis on ophthalmologic complications. Jpn J Ophthalmol. 1991;35:339-346
11. Yamamoto JH, Fujino Y, Lin C, et al. S-antigen specific T cell clones from a patient with Behçet's disease. Br J Ophthalmol. 1994;78:927-932.
12. Heymann RE, Ferraz MB, Quaresma MR, et al. The role of ambiental agents in Behçet's disease. Rev Rheum Engl Ed. 1995;62:343-348.
13. Ferraz MB, Walter SD, Heymann R, et al. Sensitivity and specificity of different diagnostic criteria for Behçet's disease according to the latent class approach. Br J Rheumatol. 1995;34:392-395.
14. Souza RC, Lage L, Goldesntein-Schainberg C, et al. Anti-endothelial cell antibodies and central nervous system involvement in Behçet's disease. Clinics (São Paulo). 2007;62:685-690.
15. Neves FR, Carrasco S, Goldenstein-Schainberg C, et al. Neutrophil hyperchemotaxis in Behçet's disease: A possible role for monocytes orchestrating bacterial-induced innate immune responses. Clin Rheumatol. 2009;28:1403-1410.
16. Zaghetto JM, Yamamoto MM, Souza MB, et al. Chlorambucil and cyclosporine A in Brazilian patients with Behçet's disease uveitis: A retrospective study. Arq Bras Oftalmol. 2010;73:40-46.
17. Aguiar SB, Guimarães S, Mesquita M, et al. Doença de Behçet: Estudo de 22 casos. Rev Bras Reumatol. 1997;37:66-74.
18. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
19. Davies PG, Fordham JN, Kirwan JR, et al. The pathergy test and Behçet's syndrome in Britain. Ann Rheum Dis. 1984;43:70-73.
20. Salvarani C, Pipitone N, Catanoso MG, et al. Epidemiology and clinical course of Behçet's disease in the Reggio Emilia Area of Northern Italy: A seventeen-year population-based study. Arthritis Rheum. 2007;57:171-178.
21. Bang D, Lee JH, Lee ES, et al. Epidemiologic and clinical survey of Behçet's disease in Korea: The first multicenter study. J Korean Med Sci. 2001;16:615-618.
22. Yazici H, Tuzun Y, Pazarli H, et al. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis. 1984;43:783-789.
23. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. Int J Dermatol. 2003;42:346-351.
24. Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Behçet's disease in 137 Italian patients: Results of a multicenter study. Clin Exp Rheumatol. 2004;22(6 suppl 2):S46YS51.
25. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behçet's disease in Greece. Clin Exp Rheumatol. 2003;21(4 suppl 30):S19YS26.
26. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. 2001;44:2686-2692.
27. Calguneri M, Ertenli I, Kiraz S, et al. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet's disease. Dermatology. 1996;192:125-128.
28. Hamuryudan V, Mat C, Saip C, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128:443-450.
29. Sharquie KE, Najim RA, Abu-Raqhif AR. Dapsone in Behçet's disease: A double-blind, placebo-controlled, cross-over study. J Dermatol. 2002;29:267-279.
30. Calgüneri M, Kiraz S, Ertenli I, et al. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behçet's. A randomized clinical trial. Arthritis Rheum. 1996;39: 2062-2065.
31. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322:281-285.
32. Mangelsdorf HC, White WL, Jorizzo JL. Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement. J Am Acad Dermatol. 1996;34:745-750.
33. Jorizzo JL, White WL, Wise CM, et al. Low-dose weekly methotrexate for unusual neutrophilic vascular reactions: Cutaneous polyarteritis nodosa and Behçet's disease. J Am Acad Dermatol. 1991;24:973-978.
34. Ozazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporine A versus pulsed cyclophosphamide in Behçet's syndrome: A single masked trial. Br J Ophthalmol. 1992;76:241-243.
35. Kötter I, Gunaydin I, Batra M, et al. CNS involvement occurs more frequently in patients with Behçet's disease under cyclosporin A (CSA) than under other medicationsVresults of a retrospective analysis of 117 cases. Clin Rheumatol. 2006;25:482-486.
36. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586-589.
37. Kato Y, Numaga J, Kato S, et al. Central nervous system symptoms in a population of Behcet's disease patients with refractory uveitis treated with cyclosporine A. Clin Exp Ophthalmol. 2001;29:335-336.
38. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: A systematic review. J Neurol. 2011;258:719-727.
39. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci. 1998;159:181-185.
40. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Behçet's disease. A follow-up study for 4 years. Adv Exp Med Biol. 2003;528:575-578.
41. Sfikakis PP, Markomichelakis N, Apsoy E, et al. Anti-TNF therapy in the management of Behçet's diseaseVreview and basis for recommendations. Rheumatology (Oxford). 2007;46:736-741.
42. Yamada Y, Sugita S, Tanaka H, et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease. Br J Ophthalmol. 2010;94:284-288.
43. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated with Behçet's disease: Immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol. 2008;27:201-205.